JP2007512381A5 - - Google Patents

Download PDF

Info

Publication number
JP2007512381A5
JP2007512381A5 JP2006541869A JP2006541869A JP2007512381A5 JP 2007512381 A5 JP2007512381 A5 JP 2007512381A5 JP 2006541869 A JP2006541869 A JP 2006541869A JP 2006541869 A JP2006541869 A JP 2006541869A JP 2007512381 A5 JP2007512381 A5 JP 2007512381A5
Authority
JP
Japan
Prior art keywords
arthritis
medicament
combination
rheumatoid arthritis
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006541869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007512381A (ja
Filing date
Publication date
Priority claimed from GBGB0327840.5A external-priority patent/GB0327840D0/en
Application filed filed Critical
Publication of JP2007512381A publication Critical patent/JP2007512381A/ja
Publication of JP2007512381A5 publication Critical patent/JP2007512381A5/ja
Pending legal-status Critical Current

Links

JP2006541869A 2003-12-01 2004-11-30 医薬的組み合わせ Pending JP2007512381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0327840.5A GB0327840D0 (en) 2003-12-01 2003-12-01 Organic compounds
PCT/EP2004/013587 WO2005053661A2 (en) 2003-12-01 2004-11-30 Pharmaceutical combinations

Publications (2)

Publication Number Publication Date
JP2007512381A JP2007512381A (ja) 2007-05-17
JP2007512381A5 true JP2007512381A5 (https=) 2008-01-24

Family

ID=29798110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006541869A Pending JP2007512381A (ja) 2003-12-01 2004-11-30 医薬的組み合わせ

Country Status (11)

Country Link
US (1) US20070117833A1 (https=)
EP (1) EP1819361A2 (https=)
JP (1) JP2007512381A (https=)
KR (1) KR20060122877A (https=)
CN (1) CN1886157A (https=)
AU (1) AU2004294282B2 (https=)
BR (1) BRPI0417146A (https=)
CA (1) CA2546738A1 (https=)
GB (1) GB0327840D0 (https=)
RU (1) RU2006123312A (https=)
WO (1) WO2005053661A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1478648E (pt) 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
WO2006053754A1 (en) * 2004-11-19 2006-05-26 Novartis Ag COMBINATIONS OF ANTI-ATHEROSCLEROTIC PEPTIDES AND AN mTOR INHIBITING AGENT AND THEIR METHODS OF USE
WO2007059106A2 (en) * 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of mntor inhibitor to treat patients with cancer
EP1880723A1 (en) * 2006-07-14 2008-01-23 Novartis AG Combination of mTOR inhibitor and antifolate compound
WO2007080124A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
KR20080090493A (ko) * 2006-02-02 2008-10-08 노파르티스 아게 결절성 경화증의 치료
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
JP2010509400A (ja) 2006-11-14 2010-03-25 アリアド・ファーマシューティカルズ・インコーポレイテッド 経口処方組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5985890A (en) * 1995-06-09 1999-11-16 Novartis Ag Rapamycin derivatives
GB0123025D0 (en) * 2001-09-25 2001-11-14 Eirx Therapeutics Ltd Apoptosis
BR0306858A (pt) * 2002-01-10 2004-11-03 Novartis Ag Sistemas de liberação de drogas para a prevenção e tratamento de doenças vasculares compreendendo rapamicina e derivados da mesma
PT1478648E (pt) * 2002-02-01 2014-07-15 Ariad Pharma Inc Compostos contendo fósforo e suas utilizações
WO2003106622A2 (en) * 2002-05-30 2003-12-24 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
TW200509958A (en) * 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Similar Documents

Publication Publication Date Title
US10561618B2 (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders
JP5796959B2 (ja) 関節炎における痛みの治療のためのタペンタドール
JP2000507544A (ja) 痛みの治療方法
WO2016062283A1 (zh) 抗发炎用药物在制备抑制癌症的医药组合物中的应用
JP2013521304A5 (https=)
CN102781240A (zh) 用拉喹莫德和甲氨蝶呤的组合治疗类风湿性关节炎
JP2008539250A (ja) アテローム性動脈硬化症を処置するための方法
JP2007512381A5 (https=)
JP2020519576A5 (https=)
EP3007693A1 (en) Pharmaceutical combinations of a pi3k inhibitor and a microtubule destabilizing agent
JP2016505050A5 (https=)
RU2007119067A (ru) Средство для лечения синдрома раздраженного кишечника с преобладанием диареи
US10576076B2 (en) Pharmaceutical combination of everolimus with dactolisib
HRP20251043T1 (hr) Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća
Kris et al. Control of chemotherapy-induced diarrhea with the synthetic enkephalin BW942C: a randomized trial with placebo in patients receiving cisplatin.
Kumar et al. Cilostazol: a new drug in the treatment intermittent claudication
US20110269755A1 (en) Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
AU2007234917B2 (en) Renin inhibitors for the treatment of hypertension
EP3789020A1 (en) Fixed dose composition of paracetamol: amitriptyline and method for the treatment of mixed cancer pain
JP2008527034A5 (https=)
MX2024004372A (es) Formulacion oral.
ZA202206042B (en) Treating behavioral and psychological symptoms in dementia patients
WO2017017511A1 (en) Modified release formulation for treating premature ejaculation
JP2004244347A (ja) イトラコナゾール併用剤
HK1207285B (en) Orally available pharmaceutical formulation suitable for improved management of movement disorders